![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: C16orf45 |
Gene summary for C16ORF45 |
![]() |
Gene information | Species | Human | Gene symbol | C16orf45 | Gene ID | 89927 |
Gene name | bMERB domain containing 1 | |
Gene Alias | C16orf45 | |
Cytomap | 16p13.11 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q96MC5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
89927 | C16orf45 | PTC01 | Human | Thyroid | PTC | 7.67e-11 | 2.61e-01 | 0.1899 |
89927 | C16orf45 | PTC04 | Human | Thyroid | PTC | 3.04e-07 | 2.46e-01 | 0.1927 |
89927 | C16orf45 | PTC05 | Human | Thyroid | PTC | 1.03e-12 | 5.27e-01 | 0.2065 |
89927 | C16orf45 | PTC06 | Human | Thyroid | PTC | 8.91e-26 | 6.00e-01 | 0.2057 |
89927 | C16orf45 | PTC07 | Human | Thyroid | PTC | 3.38e-24 | 4.75e-01 | 0.2044 |
89927 | C16orf45 | ATC09 | Human | Thyroid | ATC | 5.00e-02 | 1.33e-01 | 0.2871 |
89927 | C16orf45 | ATC12 | Human | Thyroid | ATC | 2.81e-10 | 2.52e-01 | 0.34 |
89927 | C16orf45 | ATC13 | Human | Thyroid | ATC | 1.21e-11 | 1.52e-01 | 0.34 |
89927 | C16orf45 | ATC3 | Human | Thyroid | ATC | 1.05e-03 | 2.27e-01 | 0.338 |
89927 | C16orf45 | ATC4 | Human | Thyroid | ATC | 3.26e-15 | 3.45e-01 | 0.34 |
89927 | C16orf45 | ATC5 | Human | Thyroid | ATC | 1.21e-14 | 1.68e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | CRC | ![]() |
Stomach | GC | ![]() |
Stomach | CAG with IM | ![]() |
Stomach | CSG | ![]() |
Stomach | CAG | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C16orf45 | SNV | Missense_Mutation | novel | c.471A>C | p.Lys157Asn | p.K157N | Q96MC5 | protein_coding | tolerated(0.19) | benign(0.1) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
C16orf45 | SNV | Missense_Mutation | c.173N>A | p.Ala58Glu | p.A58E | Q96MC5 | protein_coding | tolerated(0.13) | benign(0.401) | TCGA-BH-A0H0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
C16orf45 | SNV | Missense_Mutation | c.431N>C | p.Glu144Ala | p.E144A | Q96MC5 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-E9-A1RF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
C16orf45 | SNV | Missense_Mutation | c.357G>T | p.Lys119Asn | p.K119N | Q96MC5 | protein_coding | tolerated(0.06) | possibly_damaging(0.868) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
C16orf45 | SNV | Missense_Mutation | rs757365966 | c.317N>A | p.Thr106Asn | p.T106N | Q96MC5 | protein_coding | deleterious(0.01) | benign(0.01) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
C16orf45 | SNV | Missense_Mutation | rs757365966 | c.317C>A | p.Thr106Asn | p.T106N | Q96MC5 | protein_coding | deleterious(0.01) | benign(0.01) | TCGA-AA-3941-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C16orf45 | SNV | Missense_Mutation | rs757365966 | c.317N>A | p.Thr106Asn | p.T106N | Q96MC5 | protein_coding | deleterious(0.01) | benign(0.01) | TCGA-AA-3982-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
C16orf45 | SNV | Missense_Mutation | c.173C>A | p.Ala58Glu | p.A58E | Q96MC5 | protein_coding | tolerated(0.13) | benign(0.401) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD | |
C16orf45 | SNV | Missense_Mutation | c.190N>T | p.Arg64Trp | p.R64W | Q96MC5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
C16orf45 | SNV | Missense_Mutation | c.67G>A | p.Val23Met | p.V23M | Q96MC5 | protein_coding | tolerated(0.06) | benign(0.368) | TCGA-F4-6703-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |